They cannot afford to develop Lux now. Initiation of any Phase 2 trial should trigger $16M milestone payment to Crystal Genomics. Development of each drug assumes conducting studies in multiple patient populations. As a small, unprofitable biotech company you need to make your choices. Rice spent at least 2 years and a lot of money on Phase 1 trial with Lux to end up with drug precipitation in stomach. How he could possibly overlook it? Now you want him to spend substantial funds to figure out whether a new formulation works or not? It is ridiculous. Leave it to somebody who is more competent. Do a right job with Tusp, and quickly. Focus on Flt3mut inhibitor failures. With money you have, you cannot run other trials.
News 
Market Data 
Discover 
AI
